Liraglutide and sibutramine: similarities and differences in pharmacotherapy of obesity

Abstract

The centrally acting anti-obesity drugs currently registered in the Russian Federation include liraglutide 3.0 mg (Saxenda®, Enligria®) and a number of sibutramine-containing drugs, including Reduxin®, Reduxin Forte®. This literature review compares data on the mechanisms of action of these drugs and their effect on homeostatic and hedonistic regulation of body weight, production of glucagon-like peptide-1, and gut microbiota. Information is provided on the effects of these drugs on major metabolic parameters, eating behavior, and quality of life. It has been shown that, despite the significant difference in the receptor mechanisms of action, liraglutide and sibutramine-containing drugs have a similar spectrum of influence on key links in energy balance regulation and have comparable metabolic effects. Pharmacodynamic features against the background of a complex of similar metabolic effects make it possible to use the АНАЛИТИЧЕСКИЕ ОБЗОРЫ